Cargando…

Limited usefulness of calcimimetics for secondary hyperparathyroidism in non-dialysis chronic kidney disease

Detalles Bibliográficos
Autores principales:	Abbas, Fizza, Coyne, Daniel W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Nephrology 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6577219/ https://www.ncbi.nlm.nih.gov/pubmed/31189220 http://dx.doi.org/10.23876/j.krcp.19.041

Ejemplares similares

Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics
por: Arenas, Maria Dolores, et al.
Publicado: (2020)

Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2019)

Secondary Hyperparathyroidism Disease Stabilization Following Calcimimetic Therapy
por: Frazão, João, et al.
Publicado: (2008)

Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis
por: Chen, P, et al.
Publicado: (2016)

Real-World Evaluation of Calcimimetics for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease, in an Italian Clinical Setting
por: Perrone, Valentina, et al.
Publicado: (2022)

Clinical Outcomes in Secondary Hyperparathyroidism and the Potential Role of Calcimimetics
por: Cunningham, John, et al.
Publicado: (2008)

Impact of the Introduction of Calcimimetics on Timing of Parathyroidectomy in Secondary and Tertiary Hyperparathyroidism
por: van der Plas, Willemijn Y., et al.
Publicado: (2016)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs
por: Wetmore, James B, et al.
Publicado: (2008)

Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes
por: Pereira, Luciano, et al.
Publicado: (2018)

Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism
por: Ni, Zhaohui, et al.
Publicado: (2023)

Effects and Safety of Calcimimetics in End Stage Renal Disease Patients with Secondary Hyperparathyroidism: A Meta-Analysis
por: Zhang, Qian, et al.
Publicado: (2012)

Long-term effectiveness of cinacalcet in non-dialysis patients with chronic kidney disease and secondary hyperparathyroidism
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2019)

Potential Future Uses of Calcimimetics in Patients with Chronic Kidney Disease
por: Chonchol, Michel, et al.
Publicado: (2008)

Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2016)

Relationship between patients’ characteristics and efficacy of calcimimetics for primary hyperparathyroidism in the elderly
por: Yamamoto, Koichiro, et al.
Publicado: (2022)

The importance of prevention of calciphylaxis in patients who are at risk and the potential fallibility of calcimimetics in the treatment of calciphylaxis for patients with secondary hyperparathyroidism
por: Khalpey, Zain, et al.
Publicado: (2010)

Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism
por: Yu, Longchuan, et al.
Publicado: (2017)

ODP102 Indicators for the effects of calcimimetics on hypercalcemia in the elderly patients with primary hyperparathyroidism.
por: Yamamoto, Koichro, et al.
Publicado: (2022)

Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetics era
por: Conzo, Giovanni, et al.
Publicado: (2013)

Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease
por: Ketteler, Markus, et al.
Publicado: (2021)

A case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic
por: Ohya, Yuichiro, et al.
Publicado: (2018)

Role of Calcimimetics in Treating Bone and Mineral Disorders Related to Chronic Kidney Disease
por: Hou, Yi-Chou, et al.
Publicado: (2022)

Treatment of secondary hyperparathyroidism in patients on hemodialysis using a novel synthetic peptide calcimimetic, etelcalcetide: a short-term clinical study
por: Mima, Akira, et al.
Publicado: (2018)

Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s
por: Ketteler, Markus, et al.
Publicado: (2022)

Secondary hyperparathyroidism among Nigerians with chronic kidney disease
por: Gimba, Zumnan M, et al.
Publicado: (2018)

Secondary Hyperparathyroidism in Chronic Kidney Disease: Pathophysiology and Management
por: Habas, Elmukhtar, et al.
Publicado: (2021)

Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis
por: Davies, Evan W., et al.
Publicado: (2015)

Therapeutic Effect of Calcimimetics on Osteoclast–Osteoblast Crosslink in Chronic Kidney Disease and Mineral Bone Disease
por: Hung, Kuo-Chin, et al.
Publicado: (2020)

Calcimimetics in CKD—results from recent clinical studies
por: Schlieper, Georg, et al.
Publicado: (2008)

A novel case of neonatal severe hyperparathyroidism successfully treated with a type II calcimimetic drug
por: Leunbach, T.L., et al.
Publicado: (2021)

Calcimimetics and outcomes in CKD
por: Drüeke, Tilman B
Publicado: (2013)

Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan
por: Yokoyama, Keitaro, et al.
Publicado: (2020)

Paricalcitol and Extended-Release Calcifediol for Treatment of Secondary Hyperparathyroidism in Non-Dialysis Chronic Kidney Disease: Results From a Network Meta-Analysis
por: Franchi, Matteo, et al.
Publicado: (2023)

Parathyroid Cell Proliferation in Secondary Hyperparathyroidism of Chronic Kidney Disease
por: Naveh-Many, Tally, et al.
Publicado: (2020)

Outcomes of Secondary Hyperparathyroidism in Chronic Kidney Disease and the Direct Costs of Treatment
por: Joy, Melanie S., et al.
Publicado: (2007)

Novel Use of Calcimimetic Activity to Diagnose Primary Hyperparathyroidism in a Patient With Persistently Low-Normal Parathyroid Hormone Level
por: Bandaru, Sindhura, et al.
Publicado: (2020)

Calcimimetics Alter Periosteal and Perilacunar Bone Matrix Composition and Material Properties in Early Chronic Kidney Disease
por: Damrath, John G., et al.
Publicado: (2022)

Active vitamin D increases the risk of hypercalcaemia in non-dialysis chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis
por: Cozzolino, Mario, et al.
Publicado: (2021)

Association of Secondary Hyperparathyroidism with Hemoglobin Level in Patients with Chronic Kidney Disease
por: Chutia, Happy, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6h0lejormtr0uo2ch8fdphfv44